Novartis Announces Statistically Significant Reduction in Proteinuria with Fabhalta® in Phase III C3G Study
May 26, 2024
Novartis Investment Portfolios
Novartis Enhances Radiotherapy Arsenal with State-of-the-Art Manufacturing Facility for Pluvicto™ in Indianapolis
Jan 6, 2024